Related Experiment Video

Updated: May 23, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Mechanisms of LRRK2-mediated neurodegeneration

Elpida Tsika1, Darren J Moore

  • 1Laboratory of Molecular Neurodegenerative Research, Brain Mind Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne-EPFL, SV-BMI-LMNR, AI 2150, Station 15, 1015 Lausanne, Switzerland.

Current Neurology and Neuroscience Reports
|March 24, 2012
PubMed

Insights

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a leading cause of familial Parkinson's disease (PD). Understanding LRRK2's role in neurodegeneration is key to developing new PD therapies.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of familial Parkinson's disease (PD).
  • Common variations in the LRRK2 gene are linked to an increased risk of idiopathic PD.
  • LRRK2's biological functions and the mechanisms of its pathogenic mutations are increasingly understood.

Purpose of the Study:

  • To review recent advances in understanding LRRK2 pathophysiology in Parkinson's disease.
  • To highlight unanswered questions in LRRK2-mediated neurodegeneration.
  • To identify potential molecular targets for PD therapeutic intervention.

Main Methods:

  • Review of current scientific literature on LRRK2 and Parkinson's disease.
  • Analysis of findings from neuronal culture and rodent models (transgenic/viral-based).
  • Identification of pathways implicated in LRRK2-dependent neuronal damage.

Main Results:

  • LRRK2 pathways implicated in neuronal damage include microtubule network, actin cytoskeleton, autophagy, mitochondria, vesicular trafficking, and protein quality control.
  • Significant progress has been made in understanding LRRK2's biological functions and disease mechanisms.
  • Several key questions regarding LRRK2's role in neurodegeneration remain.

Conclusions:

  • Elucidating LRRK2's molecular mechanisms is critical for developing novel PD therapies.
  • Further research is needed to address outstanding questions in LRRK2 pathophysiology.
  • Targeting LRRK2 pathways offers potential for therapeutic intervention in Parkinson's disease.

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.